Generic Mayzent Availability
Last updated on Apr 10, 2025.
Mayzent is a brand name of siponimod, approved by the FDA in the following formulation(s):
MAYZENT (siponimod - tablet;oral)
-
Manufacturer: NOVARTIS
Approval date: March 26, 2019
Strength(s): EQ 0.25MG BASE [RLD], EQ 2MG BASE [RLD] -
Manufacturer: NOVARTIS
Approval date: August 24, 2021
Strength(s): EQ 1MG BASE [RLD]
Is there a generic version of Mayzent available?
No. There is currently no therapeutically equivalent version of Mayzent available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Mayzent. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
Patent 11,944,602
Issued: April 2, 2024
Inventor(s): Legangneux; Eric et al.
Assignee(s): NOVARTIS AG (Basel, CH)The present invention relates to methods of treating autoimmune diseases with siponimod in patients receiving additionally a beta-blocker.
Patent expiration dates:
- April 23, 2036✓
- April 23, 2036
-
Immunosuppressant formulations
Patent 12,071,402
Issued: August 27, 2024
Inventor(s): Bouillot; Philippe Michel Rene et al.
Assignee(s): NOVARTIS AG (Basel, CH)The present invention relates to a solid phase pharmaceutical composition comprising one or more pharmaceutically acceptable excipients and an active pharmaceutical ingredient (“API”) which is a compound of formula A1 or A2 or a pharmacologically acceptable salt, solvate or hydrate thereof, wherein the API is not exposed to a basic compound.
Patent expiration dates:
- January 5, 2032✓
- January 5, 2032
-
Immunosuppresant compounds and compositions
Patent 7,939,519
Issued: May 10, 2011
Inventor(s): Pan; Shifeng et al.
Assignee(s): Novartis AG (Basel, CH)The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.
Patent expiration dates:
- August 27, 2028✓✓
- August 27, 2028
-
Dosage regimen of an S1P receptor agonist
Patent 8,492,441
Issued: July 23, 2013
Inventor(s): Legangneux Eric
Assignee(s): Novartis AGS1P receptor modulators or agonists are administered following a dosage regimen whereby during the initial days of treatment the daily dosage is lower than the standard daily dosage.
Patent expiration dates:
- November 30, 2030✓
- November 30, 2030
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- March 1, 2025 - REVISIONS TO THE LABELING TO INCLUDE RESULTS FROM CLINICAL STUDY CBAF312A2130
More about Mayzent (siponimod)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (8)
- Imprints, shape & color data
- Side effects
- Dosage information
- Patient tips
- During pregnancy
- FDA approval history
- Drug class: selective immunosuppressants
- Breastfeeding
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.